Fig. 5From: Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United StatesCorrelation between irAEs and 18 tissue or organ disorders in different patient age groups. Correlations for ICIs targeting PD1, PDL1 and CTLA4 are shown in (A), (B) and (C), respectivelyBack to article page